Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

References

Page 1

	Year	Citations
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing Marco Gerlinger, Andrew J. Rowan, Stuart Horswell, New England Journal of Medicine	2012	7.6K
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation Caroline Robert, Georgina V. Long, Benjamin Brady, New England Journal of Medicine	2014	5.3K
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Rosandra N. Kaplan, Rebecca D. Riba, Stergios Zacharoulis, Nature Pre-metastatic NicheStem Cell MobilizationBiological MicroenvironmentsMedicineCell Biology	2005	3.2K
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, Cell Tumor ImmunologyCancer ImmunosurveillanceT-regulatory CellMelanomaImmunology	2018	2K
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou, The Lancet Oncology Tumor ImmunologyCancer ImmunosurveillanceOncologic ImagingMedicineImmunology	2018	1.2K
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Antoni Ribas, Omid Hamid, Adil Daud, JAMA	2016	1K
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis Sachie Hiratsuka, Kazuhiro Nakamura, Shinobu Iwai, Cancer Cell Mmp9 InductionAngiogenesisImmunologyCancer GrowthPathology	2002	897
Origins of tumor-associated macrophages and neutrophils Virna Cortez‐Retamozo, Martin Etzrodt, Andita Newton, Proceedings of the National Academy of Sciences	2012	672
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma Caroline Robert, Antoni Ribas, Omid Hamid, Journal of Clinical Oncology Durable Complete ResponseMedicineMelanomaImmunologyTumor Immunity	2017	477

Page 1